Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cibinetide - Araim Pharmaceuticals

Drug Profile

Cibinetide - Araim Pharmaceuticals

Alternative Names: ARA 290

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Araim Pharmaceuticals
  • Developer Araim Pharmaceuticals; Karolinska Institute; National Institute on Aging; Queens University Belfast
  • Class Analgesics; Anti-inflammatories; Antidepressants; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Hepatoprotectants; Peptides; Radioprotectives
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Neuropathic pain; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Diabetic macular oedema; Diabetic neuropathies; Neuropathic pain; Rheumatoid arthritis
  • No development reported Diabetic nephropathies; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Radiation injuries; Retinal disorders; Systemic lupus erythematosus; Transplant rejection; Wounds
  • Discontinued Depressive disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
  • 28 Jun 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
  • 28 Jun 2022 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top